Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRES: ALX1-11 Extension in Osteoporosis
NCT00172120Phase 3Completed
- Sponsor
- Takeda
- Start
- Jan 2005
- Primary completion
- Oct 2006
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of parathyroid hormone 1-84 in postmenopausal osteoporosis, sponsored by Takeda. Primary endpoint: Safety of continued once-daily dosing with 100 mg ALX1-11 at 18 months. Started Jan 2005; status: completed.
02
Drugs
parathyroid hormone 1-84
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT00172120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00172120.